Exact Sciences Q2 EPS Forecast Increased by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Leerink Partnrs increased their Q2 2025 earnings estimates for shares of Exact Sciences in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $0.03 per share for the quarter, up from their previous estimate of $0.02. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.13) per share.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. The business’s revenue was up 12.8% compared to the same quarter last year.

A number of other equities research analysts also recently weighed in on EXAS. BTIG Research lifted their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Craig Hallum dropped their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Bank of America dropped their price target on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $56.68 on Wednesday. The stock has a 50 day simple moving average of $58.33 and a 200 day simple moving average of $58.57. The stock has a market cap of $10.49 billion, a P/E ratio of -48.44 and a beta of 1.24. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Insider Activity

In other news, CEO Kevin T. Conroy acquired 19,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Exact Sciences

Several large investors have recently bought and sold shares of the company. WCM Investment Management LLC increased its stake in shares of Exact Sciences by 1,153.2% in the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after buying an additional 172,821 shares during the period. Simplify Asset Management Inc. increased its position in Exact Sciences by 67.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares during the period. Zacks Investment Management acquired a new position in Exact Sciences in the 3rd quarter valued at approximately $2,083,000. Profund Advisors LLC raised its stake in shares of Exact Sciences by 239.8% during the second quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company’s stock valued at $3,320,000 after acquiring an additional 55,459 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Exact Sciences by 59.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after purchasing an additional 125,192 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.